首頁
InnoCare Pharma Limited

7月 2026InnoCare Pharma Limited的市場佔有率分析

健康 > 生物技術和製藥

域名innocarepharma.com

成立年份2013

僱員1001 - 5000

年度營收$5M - $10M

InnoCare Pharma Limited

InnoCare Pharma Limited（包含公司地區）

innocarepharma.com

查看更多網站流量與參與度資訊

InnoCare Pharma Limited截至 7月 2026 的總收入為 5M - 10M

InnoCare Pharma Limited 熱門網域產生的總收入

InnoCare Pharma Limited 熱門網域 3 年內的總收入

InnoCare Pharma Limited 熱門網域的總收入

innocarepharma.com5M - 10M

透過銷售情報查看更多內容

InnoCare Pharma Limited的熱門網域總造訪量

了解InnoCare Pharma Limited市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

innocarepharma.com7.5K

透過銷售情報查看更多內容

InnoCare Pharma Limited的熱門網域平均造訪時長

分析InnoCare Pharma Limited參與度指標。

過去 3 個月平均造訪時長

子公司細目

innocarepharma.com00:01:10

透過銷售情報查看更多內容

InnoCare Pharma Limited的熱門網域平均頁面瀏覽量

了解InnoCare Pharma Limited如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

innocarepharma.com2.99

透過銷售情報查看更多內容

InnoCare Pharma Limited按網域劃分的熱門競爭對手

看起來這裡的數據不足

無可顯示數據

使用的熱門技術InnoCare Pharma Limited

这些是InnoCare Pharma Limited顶级域名使用的行业网站技术

轉換與分析 (4)

Google Analytics

社群 (3)

Instagram

付款與貨幣 (2)

Cart Functionality

付費廣告 (1)

Baidu Ads

更多技術

6

檢視所有

新聞與訊號來自InnoCare Pharma Limited

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞InnoCare was planning to develop experimental oral treatments on Jul 27th '26.As well as Innocare, other drugmakers including Takeda Pharmaceutical are developing experimental oral treatments.

新聞Keymed partners with Innocarepharma.PRO-203 was originally developed as CM355 by HKEX-listed KeyMed Biosciences (HKEX: 02162), subsequently co-developed with InnoCare Pharma (HKEX: 09969; SSE: 688428) as ICP-B02 under a 50/50 joint venture, and in-licensed by Prolium Bioscience in January 2025 for global non-oncology rights and ex-Asia oncology rights, with aggregate milestone payments of up to USD 520 million disclosed.

新聞Innocarepharma attended event European Hematology Association (EHA) 2026 Congress on Jun 15th '26.Beijing, June 15, 2026 - InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that over 40 clinical studies of the Company's novel BTK inhibitor orelabrutinib were presented at the European Hematology Association (EHA) 2026 Congress.